Wednesday, July 15, 2026
ISSN 2765-8767
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us
  • Home
  • Courses
  • About Us
  • Contact us
  • Support Us

Justice Department sues to block UnitedHealth Group’s $13 billion acquisition of Change Healthcare

The Department of Justice has filed a civil lawsuit to stop the $13 billion merger between UnitedHealth Group and Change Healthcare.

The complaint was filed today by the DOJ and Attorneys General in Minnesota and New York, in the U.S. District Court for the District of Columbia.

As alleged in the complaint, the proposed transaction would give United, a company that owns the largest health insurer in the United States, access to a vast amount of its rival health insurers’ competitively sensitive information, according to the DOJ.

The proposed transaction would harm competition in commercial health insurance markets, as well as in the market for technology used by health insurers to process health insurance claims, the DOJ said. It would give United control of a critical data highway of health insurance claims.

Source: Healthcare Finance

Daily Remedy

Daily Remedy

Dr. Jay K Joshi serves as the editor-in-chief of Daily Remedy. He is a serial entrepreneur and sought after thought-leader for matters related to healthcare innovation and medical jurisprudence. He has published articles on a variety of healthcare topics in both peer-reviewed journals and trade publications. His legal writings include amicus curiae briefs prepared for prominent federal healthcare cases.

Videos

Policy Shift in Peptide Regulation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

FDA Evaluation of Certain Bulk Drug Substances in Compounding: Clinical Interpretation

Clinicians increasingly encounter patients using or requesting peptide-based therapies sourced through compounding pharmacies. The U.S. Food and Drug Administration has identified a subset of bulk drug substances, including certain peptides, that may present significant safety risks when used in compounded formulations. The clinical question is whether these regulatory signals reflect meaningful patient-level risk and how they should influence prescribing behavior. This matters because compounded peptides often sit outside traditional approval pathways, creating uncertainty around quality, dosing consistency, and safety. Understanding...

Read more

Join Our Newsletter!